^
    3d
    An Exploratory Clinical Study of JV001 in the Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (ChiCTR2600117671)
    P=N/A, N=12, Completed, Shanghai East Hospital; Shanghai East Hospital
    New trial
    3d
    A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration – The STELLAR Trial (ChiCTR2500115643)
    P3, N=332, Recruiting, Shanghai General Hospital; Shanghai Langsheng Biotechnology Co., Ltd
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    3d
    A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS) (ChiCTR2600117343)
    P1/2, N=21, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New P1/2 trial
    5d
    ATA-200 Gene Therapy Trial in Patients With LGMDR5 (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Atamyo Therapeutics | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1
    Enrollment closed • Phase classification
    5d
    Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure (clinicaltrials.gov)
    P1, N=12, Suspended, Elixirgen Therapeutics, Inc. | Recruiting --> Suspended
    Trial suspension
    11d
    Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P1 trial
    12d
    ASPIRE-FTD: A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) (clinicaltrials.gov)
    P1/2, N=9, Recruiting, AviadoBio Ltd | Trial completion date: Oct 2030 --> Mar 2030
    Trial completion date
    |
    GRN (Granulin Precursor)
    13d
    Long-term Follow-up Gene Therapy Study for RPGR- XLRP (clinicaltrials.gov)
    P=N/A, N=42, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Sep 2025 | Trial primary completion date: Nov 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    13d
    Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls. (clinicaltrials.gov)
    P3, N=24, Recruiting, Elpida Therapeutics SPC | Not yet recruiting --> Recruiting
    Enrollment open
    17d
    Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (clinicaltrials.gov)
    P3, N=175, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2030 --> Feb 2031 | Trial primary completion date: Jun 2030 --> Sep 2030
    Trial completion date • Trial primary completion date
    18d
    Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002) (clinicaltrials.gov)
    P1, N=10, Completed, Xiangya Hospital of Central South University | Not yet recruiting --> Completed | Trial completion date: Dec 2028 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    22d
    A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
    P2, N=30, Recruiting, Candel Therapeutics, Inc.
    New P2 trial
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir